Search results
Results From The WOW.Com Content Network
Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. [1] [4] [6] [7] [8] Daridorexant is taken by mouth. [1] [4] [7] Side effects of daridorexant include headache, somnolence, and fatigue. [1] [7] The medication is a dual orexin receptor antagonist (DORA).
An orexin receptor antagonist, or orexin antagonist, is a drug that inhibits the effect of orexin by acting as a receptor antagonist of one (selective orexin receptor antagonist or SORA) or both (dual orexin receptor antagonis or DORA) of the orexin receptors, OX 1 and OX 2. [1]
Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”) today announce that QUVIVIQ™ (daridorexant) 25 and 50 mg has been launched and is now available in Japan as a new treatment for adults with insomnia.
Suvorexant is used for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, in adults. [2] [6] At a dose of 15 to 20 mg and in terms of treatment–placebo difference, it reduces time to sleep onset by up to 10 minutes, reduces time awake after sleep onset by about 15 to 30 minutes, and increases total sleep time by about 10 to 20 minutes. [2]
About QUVIVIQ™ QUVIVIQ™ (daridorexant) is a dual orexin receptor antagonist, that blocks the binding and activity of the wake-promoting neuropeptides known as orexins. In October 2022, daridorexant achieved positive Phase 3 top-line results in Japanese patients with insomnia and a New Drug Application was submitted in Japan in October 2023.
After Actelion was bought by Johnson & Johnson in 2017, [1] Idorsia was spun out into a new company and started operating on the same campus where Actelion was founded under the leadership of Actelion founders Jean-Paul Clozel as CEO and Martine Clozel as CSO. The company expects to be profitable in 2025.
The book Intercolonial Intimacies Relinking Latin/o America to the Philippines, 1898–1964 by Paula C. Park cites "Forzados y reclutas: los criollos novohispanos en Asia (1756-1808)" gave a higher number of later Mexican soldier-immigrants to the Philippines, pegging the number at 35,000 immigrants in the 1700s, [2] in a Philippine population ...
The history of the Philippines from 1565 to 1898 is known as the Spanish colonial period, during which the Philippine Islands were ruled as the Captaincy General of the Philippines within the Spanish East Indies, initially under the Viceroyalty of New Spain, based in Mexico City, until the independence of the Mexican Empire from Spain in 1821.